Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis

Michal Solomon*, Shoshana Greenberger, Maya Milner, Felix Pavlotzky, Aviv Barzilai, Eli Schwartz, Noa Hadayer, Sharon Baum

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The effectiveness of systemic treatment for Leishmania tropica cutaneous leishmaniasis remains unclear. The purpose of the study is to evaluate the efficacy and safety of systemic treatments for L. tropica cutaneous leishmaniasis. This retrospective study was performed in 114 patients. Systemic treatments included liposomal amphotericin B and sodium stibogluconate. All patients underwent systemic treatment for L. tropica cutaneous leishmaniasis. Favourable treatment responses were recorded in 72.5% and 70.2% of the patients in the liposomal amphotericin B and sodium stibogluconate groups, respectively; 25.3% and 46% of those in the liposomal amphotericin B and sodium stibogluconate groups respectively, experienced at least one adverse effect. Lesions in cartilaginous areas were associated with higher treatment failure. Prior topical or systemic treatment increased the chance of future systemic treatment success. Liposomal amphotericin B was associated with a shorter intravenous treatment duration and better safety profile. Thus, liposomal amphotericin B is the treatment of choice for L. tropica cutaneous leishmaniasis.

Original languageEnglish
Article numberadv00721
JournalActa Dermato-Venereologica
Volume102
DOIs
StatePublished - 2022

Keywords

  • Leishmania tropica
  • cutaneous leishmaniasis
  • liposomal amphotericin B (LAmB)
  • sodium stibogluconate
  • systemic treatment

Fingerprint

Dive into the research topics of 'Efficacy of Systemic Treatment for Leishmania tropica Cutaneous Leishmaniasis'. Together they form a unique fingerprint.

Cite this